|

HRS-4642+AG Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Ruijin Hospital1
  • Jiangsu HengRui Medicine Co., Ltd.1

Indications

  • Cancer2
  • KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting1
  • Pancreatic Cancer1

Other2 trials

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
Phase 3
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.